Elevation Oncology, Inc. (ELEV)
Elevation Oncology will go public soon. The estimated IPO date is June 25, 2021.
Stock Price: $15.00 - $17.00
Current IPO price range
| Market Cap | 365.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.40M |
| Shares Out | 22.82M |
| EPS (ttm) | -0.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
Elevation Oncology, Inc. has filed to go public with an IPO on the NASDAQ.
About ELEV
Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. We utilize our deep expertise in developing drugs for rare, genomically-defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor’s unique genomic test result can be matched with a purpose-built precision medicine. Our lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genom... [Read more...]
| Industry Biological Products | IPO Date Jun 25, 2021 |
| CEO Shawn Leland, Pharm.D., R.Ph. | Employees 8 |
| Stock Exchange NASDAQ | Ticker Symbol ELEV |